- HK$36.60bn
- HK$21.56bn
- CNY17.70bn
Brief: 3SBio Terminates Exclusive License Agreement With Astrazeneca
Brief: BlackRock's Long Position In 3Sbio Falls To 5.72% - HKEx Filing
CanSino Biologics leads slide in vaccine makers as China eases COVID curbs
Brief: HSBC Holdings PLC's Long Position In H-Shares Of 3SBio Rises To 6.23% - HKEX Filing
Brief: 3SBio Says Members Subscribed For Wealth Management Products From 1 Jan To 1 Sept
Brief: HSBC Holdings' Long Position In Ordinary Shares Of 3SBio Rises To 5.68% - HKEX Filings
Brief: CITIC Securities' Long Position In H-Share Of 3SBio Falls To 2.24% - HKEX Filing
Brief: CS Sunshine Investment's Long Position In H-Shares Of 3SBio Falls To 2.0% - HKEX Filing
Brief: 3Sbio Says HY Net Profit Attributable Increased By 6.2% To RMB954.5 Mln
Brief: 3Sbio Says Phase Iii Clinical Study Of RHTPO Injection In Pediatric ITP Indication Achieved Pre-Defined Primary Endpoint
Brief: 3SBio Proposed To Declare A Final Dividend Of HKD20 Cents Per Share For Year
China's 3SBio jumps most since late August on robust earnings estimates
Brief: 3Sbio Sees Net Profit & Profit Attributable For Year Will Record Increase Ranging From 100% To 120% And 90% To 110%, Respectively
Brief: 3Sbio Says Application For Launch Of 5% Minoxidil Foam Submitted To NMPA Of PRC Was Accepted
Brief: 3Sbio Says Unit And Syncromune To Develop And Commercialize Sunshine Guojian's Anti-Pd-1 Antibody 609A
Brief: BlackRock's Long Position In 3SBio Rises To 7.42% - HKEx Filing
Brief: 3Sbio Says Phase III Clinical Trial Of 5% Minoxidil Foam Reached Preset End Point
Brief: 3Sbio Posts HY Net Profit Attributable RMB898.9 MLN, Increased By 28.0%
Brief: 3Sbio Says Study On Narfuraphine Hydrochloride Tablets Reached Preset Clinical Study Endpoint